BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company, today announced the successful completion of an analytical validation study of its MenaCalc™ clinical test, which demonstrated strong overall assay performance and precision with mean coefficient of variation (%CV) of only 2.3% (Range 0.07-6.95). MenaCalc™ is a next generation driver-based prognostic test to predict the risk of developing cancer metastasis in patients with invasive breast cancer, squamous cell carcinoma of the lung and a number of additional epithelial-based cancer tumors. The MenaCalc™ results, reported as a MenaCalc™ Score, better inform physicians in making treatment decisions to enhance outcomes.
“With successful analytical validation we are now advancing into our clinical validation studies with confidence,” stated Mark Gustavson, PhD, Vice President Diagnostics of MetaStat. “Analytical precision is a prerequisite for clinical accuracy.”
In this study, MetaStat assessed the overall assay performance, imaging, and scoring performance of the fully-automated quantitative immunofluorescence clinical MenaCalc™ test using FFPE tissue samples (n=28) from patients with invasive breast cancer. MenaCalc™ was shown to have strong assay performance (day-to-day reproducibility) as measured by linear regression analysis showing Pearson’s R greater than 0.85 and linear slopes greater than 0.98 with a mean %CV of 2.3% (Range 0.07-6.95). Further, imaging and scoring performance (run-to-run precision) was also highly precise with Pearson’s R and linear slopes greater than 0.99 as well as %CV of 0.45% (Range 0.02-2.32).
“Findings published online, in BMC Cancer in June 2015, demonstrated the value of MenaCalc™ as a prognostic marker for survival in patients with node-negative invasive breast cancer,” stated Douglas A. Hamilton, President and CEO of MetaStat. “We are excited and look forward to providing physicians with commercial access to our MenaCalc™ test later this year, after we complete our clinical validation program. Data from the clinical program will support physicians’ decision to use the test and payors to reimburse for it.”
About MenaCalc™
MenaCalc™ is a quantitative immunofluorescent tissue-based assay which measures expression levels of the Mena protein and its non-invasive isoform Mena11A. The MenaCalc™ diagnostic platform is prognostic for metastatic risk and has the potential to predict outcome in multiple epithelial-based tumor types including breast cancer, prostate cancer, Non-Small Cell Lung Cancer (NSCLC), and colorectal cancer (CRC). The Mena protein and its isoforms are key potentiators and modulators of cellular phenotype and migration and are central to the metastatic cascade. Overexpression of MenaINV and down regulation of Mena11a in tumor cells correlate with increased metastatic potential. We believe MenaCalc™ predicts outcome and metastatic risk for the majority of invasive breast cancer patients including the HER2-positive and Triple Negative (TNC) subtypes for which there is no viable diagnostic on the market currently.
About MetaStat, Inc.
MetaStat, develops and commercializes tissue-based diagnostic tests for prediction of cancer metastasis. MetaStat is focused on breast, lung, colorectal and prostate cancers, where aggressive cancer is responsible for approximately 90% of all deaths. MetaStat's driver-based diagnostic platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on the aggressiveness of their tumor and risk the cancer will spread. MetaStat's testing platform improves treatment planning decisions by positively identifying patients at high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.